ONO-7475-04:A Phase1 study of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and ONO-7475 in combination with GnP in patients with pancreatic cancer
Phase 1
Recruiting
- Conditions
- metastatic pancreatic cancer
- Registration Number
- JPRN-jRCT2031230429
- Lead Sponsor
- Hirashima Yoshinori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 87
Inclusion Criteria
1.Patient with metastatic pancreatic cancer
2.Patients have an ECOG performance status of 0 to 1
3.Patients with a life expectancy of at least 6 months
Exclusion Criteria
1.Patients are unable to swallow oral medications
2.Patients with severe complication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and tolerability
- Secondary Outcome Measures
Name Time Method Efficacy, pharmacokinetics and immunogenicity